Determining the supportive care needs, and distress, of Australian men with prostate cancer receiving hormone therapy: A cross-sectional study.

Helen Crowe, Nicholas Howard, Brindha Pillay, Peter Xiberras, Catherine Paterson, Charlotte Primeau

Research output: Contribution to conference (non-published works)Abstract

Abstract

The mainstay treatment for metastatic prostate cancer disease aims to reduce systemic testosterone levels, which can be achieved surgically or by chemical castration, known as androgen deprivation therapy (ADT).
Original languageEnglish
Pages17-17
Number of pages1
Publication statusPublished - 2018
Event19th Asia-Pacific Prostate Cancer Conference - Brisbane Convention Centre, Brisbane, Australia
Duration: 22 Aug 201825 Aug 2018

Conference

Conference19th Asia-Pacific Prostate Cancer Conference
Abbreviated titleAPPC 2018
CountryAustralia
CityBrisbane
Period22/08/1825/08/18

Fingerprint Dive into the research topics of 'Determining the supportive care needs, and distress, of Australian men with prostate cancer receiving hormone therapy: A cross-sectional study.'. Together they form a unique fingerprint.

  • Cite this

    Crowe, H., Howard, N., Pillay, B., Xiberras, P., Paterson, C., & Primeau, C. (2018). Determining the supportive care needs, and distress, of Australian men with prostate cancer receiving hormone therapy: A cross-sectional study.. 17-17. Abstract from 19th Asia-Pacific Prostate Cancer Conference, Brisbane, Australia.